Page 1

● July - September Financial summary for the quarter Net turnover amounted to SEK 0.8 ( 1.1 ) million . The loss before interest , tax , depreciation and amortization ( EBITDA ) amounted to SEK -11.7 ( 5.2 ) million . Basic and diluted earnings per share amounted to SEK -0.26 ( 0.19 ) and SEK -0.26 ( 0.19 ) respectively . ● ● MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2021 ● Positive MIV - 818 data presented at ESMO . New positive data and renegotiated agreement for remetinostat Significant events during the quarter In July , Malene Jensen was appointed Vice President Clinical Development . She took on her position in early September . Cash flow from operating activities amounted to SEK -20.0 ( -17.1 ) million . Liquid assets and short - term investments at the end of the period amounted to SEK 225.9 ( 82.7 ) million . In August , the positive results from the phase II study with remetinostat against basal cell carcinoma ( BCC ) were published in the scientific journal Clinical Cancer Research . MEDIVIR In August , it was announced that Medivir , through a renegotiated multi - party agreement , strengthens the business development potential for remetinostat . End of August , Medivir received regulatory approval from the British UK Medicines & Healthcare products Regulatory Agency ( MHRA ) for the upcoming phase 1b / 2a combination study with MIV - 818 against liver cancer . At the ESMO Congress in September , the results from the completed dose escalation part of the phase 1b monotherapy study with MIV - 818 were presented . Medivir presented the data at a conference call on the same day . January - September Financial summary for the period Net turnover amounted to SEK 11.6 ( 12.5 ) million . The loss before interest , tax , depreciation and amortization ( EBITDA ) amounted to SEK -36.0 ( -27.9 ) million . Basic and diluted earnings per share amounted to SEK -0.80 ( -1.30 ) and SEK -0.80 ( -1.30 ) respectively . Cash flow from operating activities amounted to SEK -43.3 ( -57.1 ) million . Liquid assets and short - term investments at the end of the period amounted to SEK 225.9 ( 82.7 ) million . Significant events after the end of the period In October , the Board of Directors appointed Jens Lindberg as new CEO of Medivir . Jens Lindberg has extensive experience from the pharmaceutical industry and the field of Oncology . He joins from Sedana Medical where he has been VP Commercial Operations and acting CEO . Medivir in brief Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high . The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients . Medivir is focusing on the development of MIV - 818 , a pro - drug designed to selectively treat liver cancer cells and to minimize side effects . Collaborations and partnerships are important parts of Medivir's business model , and the drug development is conducted either by Medivir or in partnership . Birinapant , a SMAC mimetic , is exclusively outlicensed to IGM Biosciences ( Nasdaq : IGMS ) to be developed in combination with IGM - antibodies for the treatment of solid tumors . Medivir's share ( ticker : MVIR ) is listed on Nasdaq Stockholm's Small Cap list . www.medivir.com Medivir AB ( publ ) , 556238-4361 . PO Box 1086 , SE - 141 22 Huddinge , Sweden . Telephone +46 ( 0 ) 8-5468 3100 . info@medivir.se | www.medivir.com 1